False Claims (Whistleblower)
A False Claims Act investigation does not begin the moment a lawsuit is filed. By the time a provider, hospital, or medical company receives notice that a qui tam complaint has been filed against them, the government may have spent months — or years — quietly building its case. Understanding how this process works, and what is truly at stake, is the first step toward mounting an effective defense.
What Is the False Claims Act?
The False Claims Act (FCA), 31 U.S.C. §§ 3729–3733, is the federal government’s primary weapon against fraud involving taxpayer-funded programs. Originally enacted during the Civil War to combat defense contractor fraud, it has since become the cornerstone of Medicare and Medicaid fraud enforcement. The FCA imposes civil liability on any person or entity that knowingly submits — or causes the submission of — a false or fraudulent claim for payment to the federal government.
The penalties are severe: each false claim carries a civil penalty of approximately $13,000 to $27,000 per violation, plus three times the amount of damages sustained by the government (treble damages). In healthcare fraud cases involving thousands of individual claims, exposure can reach tens of millions of dollars — even where the underlying billing errors were unintentional.
Critical distinction: The FCA does not require proof of specific intent to defraud. “Knowingly” under the statute includes acting in reckless disregard or deliberate ignorance of the truth. A billing department that ignores obvious red flags, or fails to correct known errors, can face the same liability as one that deliberately submits fraudulent claims.
How Qui Tam Lawsuits Work
A distinctive and powerful feature of the FCA is its qui tam provision, which allows private citizens — known as relators or whistleblowers — to file lawsuits on behalf of the United States government. These relators are typically current or former employees, competitors, or contractors with insider knowledge of the alleged fraud.
When a qui tam complaint is filed, it is placed under seal — meaning the defendant is not notified. During this sealed period, which can last one to several years, the Department of Justice and relevant agencies (typically HHS-OIG) conduct a confidential investigation. They may interview witnesses, review billing data, issue Civil Investigative Demands, and gather evidence — all without the defendant’s knowledge.
If the government elects to intervene, it takes over primary responsibility for the case and the relator steps into a supporting role. If the government declines to intervene, the relator may still proceed with the lawsuit independently. Either path can result in substantial liability for the defendant.
Whistleblowers who prevail in qui tam cases are entitled to receive 15–30% of the government’s recovery — creating a powerful financial incentive to come forward with allegations of fraud.
What Triggers a False Claims Act Investigation
FCA investigations are initiated through several channels. Qui tam lawsuits by relators are the most common trigger. But investigations also arise from:
- Data mining and statistical analysis by CMS contractors identifying billing anomalies
- Referrals from the HHS Office of Inspector General following audits or hotline complaints
- Information developed during a parallel criminal investigation
- Competitor complaints or referrals from other healthcare entities
- Routine Medicare or Medicaid audits by RACs, ZPICs, or MACs that uncover patterns suggesting systemic fraud
Regardless of the trigger, the investigative process follows a similar trajectory: documents are gathered, financial records are analyzed, and the government builds a picture of the alleged scheme before the defendant even knows they are under scrutiny.
The Government Intervention Decision
After its investigation, the DOJ must decide whether to intervene — that is, whether to take over the lawsuit and pursue it in the government’s name. This decision is among the most consequential moments in an FCA case. Government intervention significantly increases the pressure on the defendant: the full resources of the DOJ and relevant federal agencies are brought to bear, and settlement demands typically escalate.
When the government intervenes, cases rarely go to trial. The vast majority resolve through settlement agreements in which the defendant pays a negotiated amount (often including a multiplier) and, in many cases, enters into a Corporate Integrity Agreement (CIA) with HHS-OIG requiring ongoing compliance monitoring. Understanding what drives the government’s intervention decision — and how to influence it before the case becomes public — is one of the most valuable things an experienced defense attorney can do.
Pre-intervention strategy matters: In some cases, a proactive disclosure to the government — made before the DOJ formally intervenes — can dramatically reduce exposure. This is especially true when the conduct was inadvertent, limited in scope, or already self-corrected. Early, voluntary cooperation sends a powerful signal and can influence the government’s view of the case.
Common Healthcare FCA Theories
In the healthcare context, the most frequently asserted FCA theories include:
- Billing for services not rendered — submitting claims for treatments or procedures that never occurred
- Upcoding — billing for a higher-complexity service than was actually provided
- Medically unnecessary services — submitting claims for services that lack proper clinical documentation or justification
- Anti-Kickback Statute violations — claims tainted by unlawful referral arrangements are deemed false under the FCA
- Stark Law violations — claims submitted in violation of physician self-referral prohibitions may constitute false claims
- Reverse false claims — improperly retaining overpayments owed back to the government
Whistleblower Retaliation Claims
The FCA also contains robust anti-retaliation provisions protecting employees who report fraud or assist in FCA investigations. Under 31 U.S.C. § 3730(h), an employee who is discharged, demoted, harassed, or otherwise discriminated against for engaging in protected whistleblower activity is entitled to reinstatement, double back pay, and attorneys’ fees.
For healthcare employers, this means that terminating an employee who has complained internally about billing practices — even if those complaints are unfounded — can trigger independent legal exposure separate from any underlying FCA case. Managing whistleblower situations carefully, from the moment a complaint is raised, is essential to limiting this risk.
Defending Against False Claims Act Allegations
A strong FCA defense begins with understanding the specific theory the government or relator is pursuing. Not every billing error — and not every audit finding — constitutes a false claim. The government must prove that the defendant acted knowingly, that the claims submitted were actually false, and that the falsity was material to the government’s payment decision.
Effective defenses often focus on the absence of scienter (knowledge or intent), the government’s consistent reimbursement of similar claims (undermining materiality), ambiguity in the applicable billing guidance, or the relator’s lack of credibility and improper motive. In appropriate cases, filing a motion to dismiss under Rule 9(b) — which requires fraud to be pled with particularity — can dispose of inadequately supported qui tam complaints before significant resources are expended.
Facing a False Claims Act Investigation?
Whether you have received a Civil Investigative Demand, learned of a sealed qui tam lawsuit, or are negotiating with the DOJ, the decisions you make in the early stages will define your options. As a former federal prosecutor, Justo Mendez understands how the government builds these cases — and how to defend them.